Merck’s Patent Pool Offer Not Enough for Global Access
27 October 2021
In response to Merck’s announcement that it has granted a license for its promising COVID-19 pill to the Medicines Patent Pool, Robbie Silverman, Oxfam America’s Senior Manager for Private Sector Engagement, made the following statement:
“Merck’s move to license molnupiravir is welcome as it could indeed mean increased access to its promising COVID-19 drug in the poorest countries in the world.